Aardvark Therapeutics, Inc.（AARD）价格预测AARDAardvark Therapeutics, Inc.

Alphio's AARD stock price prediction model matches the current Aardvark Therapeutics, Inc. tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $5.75 (-0.72%). The 1-week path is $5.87 (+1.35%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Aardvark Therapeutics is not a good buy right now due to significant operational and financial challenges. The stock is currently priced at $5.79, which is down 56.10% year-to-date and has a troubling RSI of 33.457, indicating it is oversold. Furthermore, the company faces a full clinical hold on its lead drug ARD-101, which has led to a net loss of $14.4 million in Q2 2026, unchanged from the previous year. Analyst ratings have been downgraded, with BofA setting a target of $4, reflecting a lack of confidence in the company's future prospects. The main risk is the ongoing FDA clinical hold, which has already resulted in a 30% drop in stock price following its announcement.

Aardvark Therapeutics, Inc. (AARD) last closed at $5.79, losing -12.54%. These facts feed the 1-day and 1-week AARD price prediction above.